THERAGEN ETEX CO.,LTD. Logo

THERAGEN ETEX CO.,LTD.

A biotech firm offering gene analysis and developing personalized cancer drugs.

066700 | KO

Overview

Corporate Details

ISIN(s):
KR7066700006
LEI:
Country:
South Korea
Address:
경기도 안산시 단원구 산단로 68번길 58(초지동), 안산시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

THERAGEN ETEX CO., LTD. is a biotechnology and pharmaceutical company specializing in genome-based personalized and precision medicine. The company integrates two core capabilities: advanced gene analysis and pharmaceutical development. Its genomics division provides high-level genome sequencing and analysis services, having achieved milestones such as creating the world's first female and tiger genome maps. The pharmaceutical division operates international GMP-certified facilities to manufacture and supply medicines. It focuses on developing a new drug pipeline that includes incrementally modified drugs, orphan drugs, and novel anticancer treatments. A key candidate, Vactosertib, is currently undergoing clinical trials in Korea and the U.S. for various cancers. This synergistic approach positions the company at the forefront of personalized healthcare solutions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.6 MB
2025-07-30 00:00
Earnings Release
영업(잠정)실적(공정공시)
Korean 14.3 KB
2025-07-30 00:00
Management Discussion and Analysis
영업실적등에대한전망(공정공시)
Korean 10.6 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.2 MB
2025-05-08 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 10.1 KB
2025-05-08 00:00
Earnings Release
연결재무제표기준영업(잠정)실적(공정공시)
Korean 16.9 KB
2025-05-08 00:00
Earnings Release
영업(잠정)실적(공정공시)
Korean 14.4 KB
2025-04-30 00:00
Regulatory News Service
소속부변경
Korean 3.6 KB
2025-04-22 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-04-18 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 5.6 KB
2025-04-10 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 94.8 KB
2025-03-27 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 19.8 KB
2025-03-24 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
Korean 40.7 KB
2025-03-21 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 99.7 KB
2025-03-21 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 97.7 KB

Automate Your Workflow. Get a real-time feed of all THERAGEN ETEX CO.,LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for THERAGEN ETEX CO.,LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for THERAGEN ETEX CO.,LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden
ACTI
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing a novel GSK-3 inhibitor for hard-to-treat cancers.
United States of America
ACTU
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden
ACUC
Acurx Pharmaceuticals, Inc. Logo
Developing a new class of antibiotics to treat priority Gram-positive bacterial infections.
United States of America
ACXP
Adagene Inc. Logo
Develops novel antibody-based immunotherapies for cancer using an AI-driven discovery platform.
United States of America
ADAG
Adaptimmune Therapeutics PLC Logo
Develops novel T-cell therapies to treat solid tumors by engineering a patient's own immune cells.
United States of America
ADAP
ADBIOTECH Co.,Ltd. Logo
Develops egg-based IgY antibodies as vaccine/antibiotic alternatives for animal and human health.
South Korea
179530
ADC Therapeutics SA Logo
Develops targeted antibody-drug conjugates for hematological and solid tumors.
United States of America
ADCT
ADIAL PHARMACEUTICALS, INC. Logo
Develops personalized, genetically-targeted drugs for treating Alcohol Use Disorder and addiction.
United States of America
ADIL
Adicet Bio, Inc. Logo
Developing off-the-shelf gamma delta T cell therapies for cancer and autoimmune diseases.
United States of America
ACET

Talk to a Data Expert

Have a question? We'll get back to you promptly.